First National Bank of Mount Dora Trust Investment Services decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 36.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,077 shares of the company’s stock after selling 6,400 shares during the period. First National Bank of Mount Dora Trust Investment Services’ holdings in Eli Lilly and were worth $948,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Acrospire Investment Management LLC grew its stake in shares of Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC bought a new stake in shares of Eli Lilly and during the second quarter valued at approximately $128,000. San Francisco Sentry Investment Group CA bought a new stake in shares of Eli Lilly and during the second quarter valued at approximately $129,000. Point72 Asia Hong Kong Ltd grew its stake in shares of Eli Lilly and by 237.4% during the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after purchasing an additional 1,239 shares during the last quarter. Finally, Shine Investment Advisory Services Inc. bought a new stake in shares of Eli Lilly and during the second quarter valued at approximately $148,000. 76.45% of the stock is owned by institutional investors.

Eli Lilly and Company (LLY) opened at $85.32 on Friday. Eli Lilly and Company has a 52 week low of $65.96 and a 52 week high of $89.09. The stock has a market cap of $93,196.69, a P/E ratio of 20.69, a price-to-earnings-growth ratio of 1.86 and a beta of 0.35. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period last year, the business posted $0.88 earnings per share. equities research analysts predict that Eli Lilly and Company will post 4.21 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a yield of 2.44%. Eli Lilly and’s dividend payout ratio (DPR) is presently 98.58%.

Several analysts have recently commented on LLY shares. Credit Suisse Group cut shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and increased their price target for the company from $84.23 to $88.00 in a research note on Tuesday, October 10th. Piper Jaffray Companies reissued a “buy” rating and set a $103.00 price target on shares of Eli Lilly and in a research note on Thursday, August 31st. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price objective on the stock in a research note on Thursday, October 26th. Jefferies Group reaffirmed a “buy” rating and issued a $89.00 price objective (down from $94.00) on shares of Eli Lilly and in a research note on Thursday, August 24th. Finally, BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the company a “sell” rating in a research note on Wednesday, November 1st. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the company’s stock. Eli Lilly and currently has a consensus rating of “Hold” and an average target price of $90.25.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 195,000 shares of the stock in a transaction on Friday, September 29th. The shares were sold at an average price of $85.14, for a total value of $16,602,300.00. Following the sale, the insider now directly owns 123,513,247 shares in the company, valued at $10,515,917,849.58. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares in the company, valued at $3,646,338.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 592,003 shares of company stock worth $50,246,641. Company insiders own 0.20% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Eli Lilly and Company (LLY) Stake Decreased by First National Bank of Mount Dora Trust Investment Services” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/12/02/eli-lilly-and-company-lly-stake-decreased-by-first-national-bank-of-mount-dora-trust-investment-services.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.